logoCabeceraNinos

Hemos leído sobre ... Tratamientos

Última actualización: 21 Febrero 2018
 
 
 
ENERO 2019
  • Nagy A, Mátrai P, Hegyi P, Alizadeh H, Bajor J, Czopf L, Gyöngyi Z, Kiss Z, Márta K, Simon M, Szilágyi ÁL, Veres G, Mosdósi B.
    The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis.
    Pediatr Rheumatol Online J. 2019 Jan 18;17(1):4. doi: 10.1186/s12969-019-0305-x.
    https://www.ncbi.nlm.nih.gov/pubmed/30658717
 
DICIEMBRE 2018
  • Abreu P, Ávila-Pedretti G, Morel Z, Acosta MI, Cabrera-Villalba S, Melgarejo P, Franco M, Delgadillo P, Román L, Elizaur JG, Paredes E, Cordovilla DO, Palleiro D, Albanese M, Mazzoleni J.
    Seguridad y supervivencia de las terapias biológicas: Primer informe del registro paraguayo-uruguayo de acontecimientos adversos con terapias biológicas. Biobadaguay.
    Reumatol Clin. 2018 Dec 27. pii: S1699-258X(18)30189-X. doi: 10.1016/j.reuma.2018.08.009. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/30595458
  • Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, Panaviene V, Bader-Meunier B, Anton J, Nielsen S, De Benedetti F, Kamphuis S, Staņēviča V, Tracahana M, Ailioaie LM, Tsitsami E, Klein A, Minden K21,22, Foeldvari I, Haas JP, Klotsche J, Horne AC, Consolaro A, Bovis F, Bagnasco F, Pistorio A, Martini A, Wulffraat N, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO), BiKeR and the board of the Swedish Registry.
    Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Arthritis Res Ther. 2018 Dec 27;20(1):285. doi: 10.1186/s13075-018-1780-z.
    https://www.ncbi.nlm.nih.gov/pubmed/30587248
  • Jung JY, Kim MY, Suh CH, Kim HA.
    Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review.
    Pediatr Rheumatol Online J. 2018 Dec 14;16(1):79. doi: 10.1186/s12969-018-0296-z.
    https://www.ncbi.nlm.nih.gov/pubmed/30547812
  • Lyseng-Williamson KA.
    Anakinra in Still's disease: a profile of its use.
    Drugs Ther Perspect. 2018;34(12):543-553. doi: 10.1007/s40267-018-0572-5. Epub 2018 Oct 31.
    https://www.ncbi.nlm.nih.gov/pubmed/30546251
 
NOVIEMBRE 2018
  • Aygun D, Sahin S, Adrovic A, Barut K, Cokugras H, Camcıoglu Y, Kasapcopur O.
    The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study.
    Clin Rheumatol. 2018 Nov 17. doi: 10.1007/s10067-018-4367-9. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/30448935
  • Klein A, Becker I, Minden K, Foeldvari I, Haas JP, Horneff G
    Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
    Scand J Rheumatol. 2018 Nov 9:1-10. doi: 10.1080/03009742.2018.1488182. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30411654
 
OCTUBRE 2018
  • Aeschlimann FA, Chong SL, Lyons TW, Beinvogl BC, Góez-Mogollón LM, Tan S, Laxer RM.
    Risk of Serious Infections Associated with Biologic Agents in Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analyses
    J Pediatr. 2018 Oct 11. pii: S0022-3476(18)31239-3. doi: 10.1016/j.jpeds.2018.08.065. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30318371
  • Keppeke LF, Molina J, Miotto E Silva VB, Terreri MTSELRA, Keppeke GD, Schoen TH, Len CA.
    Psychological characteristics of caregivers of pediatric patients with chronic rheumatic disease in relation to treatment adherence.
    Pediatr Rheumatol Online J. 2018 Oct 12;16(1):63. doi: 10.1186/s12969-018-0280-7.
    https://www.ncbi.nlm.nih.gov/pubmed/30314523
 
SEPTIEMBRE 2018
  • Hunter H.
    Etanercept or adalimumab: which is a better biological therapy for juvenile idiopathic arthritis?
    Arch Dis Child. 2018 Sep 27. pii: archdischild-2018-315528. doi: 10.1136/archdischild-2018-315528. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30262509
  • Cabrera N, Lega JC, Kassai B, Wouters C, Kondi A, Cannizzaro E, Woerner A, Chausset A, Roethlisberger S, Jeanneret C, Aeschlimann F, Malik S, Duquesne A, Kaiser D, Higel L, Maes A, Berthet G, Hentgen V, Kone-Paut I, Belot A, Hofer M.
    Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohorte database.
    Joint Bone Spine. 2018 Sep 7. pii: S1297-319X(18)30283-5. doi: 10.1016/j.jbspin.2018.08.003. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30201476
  • Nieto-González JC, Monteagudo I
    Estado actual del tratamiento con infiltraciones intraarticulares en la artritis idiopática juvenil
    Reumatol Clin. 2018 Sep 19. pii: S1699-258X(18)30174-8. doi: 10.1016/j.reuma.2018.07.015. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30243614
  • Ruiz-Medrano J, Díaz-Valle D, Cuiña R, Gegúndez JA, Chhablani J, Majumder PD, Gutierrez-Bonet R.
    The role of tocilizumab in the treatment of inflammatory diseases of the eye and orbit: A useful alternative.
    J Fr Ophtalmol. 2018 Sep 11. pii: S0181-5512(18)30282-1. doi: 10.1016/j.jfo.2018.02.006. [Epub ahead of print] 

    https://www.ncbi.nlm.nih.gov/pubmed/30217605
  • Chi H, Teng J, Yang C, Su Y.
    Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNFα therapy.
    Immunotherapy. 2018 Sep;10(12):1033-1039.
    https://www.ncbi.nlm.nih.gov/pubmed/30185135
 
AGOSTO 2018
  • Randell RL, Adams AV, Van Mater H.
    Tocilizumab in Refractory Autoimmune Encephalitis: A Series of Pediatric Cases.
    Pediatr Neurol. 2018 Aug 3. pii: S0887-8994(18)30366-7. doi: 10.1016/j.pediatrneurol.2018.07.016. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30177347
  • Nijhof LN, Nap-van der Vlist MM, van de Putte EM, van Royen-Kerkhof A, Nijhof SL.
    Non-pharmacological options for managing chronic musculoskeletal pain in children with pediatric rheumatic disease: a systematic review.
    Rheumatol Int. 2018 Aug 23. doi: 10.1007/s00296-018-4136-8. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30155667
  • Higgins GC.
    Complications of Treatments for Pediatric Rheumatic Diseases.
    Pediatr Clin North Am. 2018 Aug;65(4):827-854. doi: 10.1016/j.pcl.2018.04.008.
    https://www.ncbi.nlm.nih.gov/pubmed/30031500
 
JULIO 2018
  • Horneff G, Seyger MMB, Arikan D, Kalabic J, Anderson JK, Lazar A, Williams DA, Wang C, Tarzynski-Potempa R, Hyams JS.
    Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
    J Pediatr. 2018 Jul 25. pii: S0022-3476(18)30755-8. doi: 10.1016/j.jpeds.2018.05.042. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30054164
  • Skrabl-Baumgartner A, Seidel G, Langner-Wegscheider B, Schlagenhauf A, Jahnel J.
    Drug monitoring in long-term treatment with adalimumab for juvenile idiopathic arthritis-associated uveitis.
    Arch Dis Child. 2018 Jul 19. pii: archdischild-2018-315060. doi: 10.1136/archdischild-2018-315060. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30026253
  • Ferrara G, Mastrangelo G, Barone P, La Torre F, Martino S, Pappagallo G, Ravelli A, Taddio A, Zulian F, Cimaz R; Rheumatology Italian Study Group
    Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.
    Pediatr Rheumatol Online J. 2018 Jul 11;16(1):46. doi: 10.1186/s12969-018-0255-8.
    https://www.ncbi.nlm.nih.gov/pubmed/29996864
  • Bharucha KN, Brunner HI, Calvo Penadés I, Nikishina I, Rubio-Pérez N, Oliveira S, Kobusinska K, Schmeling H, Sztajnbok F, Weller-Heinemann F, Zholobova E, Zulian F, Allen R, Chaitow J, Frane J, Wells C, Ruperto N, De Benedetti F; Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group.
    Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial.
    J Rheumatol. 2018 Aug;45(8):1173-1179. doi: 10.3899/jrheum.170326. Epub 2018 Jul 1.
    https://www.ncbi.nlm.nih.gov/pubmed/29961686
 
JUNIO 2018
  • Lovell DJ, Dare JA, Francis-Sedlak M, Ball J, LaMoreaux BD, Von Scheven E, Reinhardt A, Jerath R, Alpan O, Gupta R, Goldsmith D, Zeft A, Naddaf H, Gottlieb B, Jung L, Holt RJ.
    A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2018 Jun 26;16(1):41. doi: 10.1186/s12969-018-0260-y
    https://www.ncbi.nlm.nih.gov/pubmed/29941047
  • Saint-Georges V, Peternel S, Kaštelan M, Brajac I.
    Tumor Necrosis Factor Antagonists in the Treatment of Pyoderma Gangrenosum, Acne, and Suppurative Hidradenitis (PASH) Syndrome.
    Acta Dermatovenerol Croat. 2018 Jun;26(2):173-178
    https://www.ncbi.nlm.nih.gov/pubmed/29989876
  • Emmi G, Urban ML, Imazio M, Gattorno M, Maestroni S, Lopalco G, Cantarini L, Prisco D, Brucato A.
    Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.
    Curr Cardiol Rep. 2018 Jun 14;20(8):61. doi: 10.1007/s11886-018-1007-6
    https://www.ncbi.nlm.nih.gov/pubmed/29904899
  • Xu C, Peng H, Li R, Chai W, Li X, Fu J, Liu K, Yu B, Jia C, Chen J.
    Risk factors and clinical characteristics of deep knee infection in patients with intra-articular injections: A matched retrospective cohort analysis.
    Semin Arthritis Rheum. 2018 Jun;47(6):911-916. doi: 10.1016/j.semarthrit.2017.10.013
    https://www.ncbi.nlm.nih.gov/pubmed/29129326
  • Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R.
    JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
    J Clin Invest. 2018 Jun 11. pii: 98814. doi: 10.1172/JCI98814
    https://www.ncbi.nlm.nih.gov/pubmed/29649002
  • Brucato A, Emmi G, Cantarini L, Di Lenarda A, Gattorno M, Lopalco G, Marcolongo R, Imazio M, Martini A, Prisco D.
    Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism.
    Intern Emerg Med. 2018 Jun;13(4):475-489. doi: 10.1007/s11739-018-1842-x
    https://www.ncbi.nlm.nih.gov/pubmed/29633070
 
MAYO 2018
  • Ringold S, Nigrovic PA, Feldman BM, Tomlinson GA, von Scheven E, Wallace CA, Huber AM, Schanberg LE, Li SC, Weiss PF, Fuhlbrigge RC, Morgan EM, Kimura Y.
    The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans: Toward Comparative Effectiveness in the Pediatric Rheumatic Diseases.
    Arthritis Rheumatol. 2018 May;70(5):669-678. doi: 10.1002/art.40395. Epub 2018 Mar 31.
    https://www.ncbi.nlm.nih.gov/pubmed/29333701
  • Poddighe D, Romano M, Gattinara M, Gerloni V.
    Biologics for the treatment of Juvenile Idiopathic Arthritis.
    Curr Med Chem. 2018 May 21. doi: 10.2174/0929867325666180522085716. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29788871
  • De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G.
    Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    N Engl J Med. 2018 May 17;378(20):1908-1919. doi: 10.1056/NEJMoa1706314.
    https://www.ncbi.nlm.nih.gov/pubmed/29768139
  • Yazılıtaş F, Aydoğ Ö, Özlü SG, Çakıcı EK, Güngör T, Eroğlu FK, Gür G, Bülbül M.
    Canakinumab treatment in children with familial Mediterranean fever: report from a single center
    Rheumatol Int. 2018 May;38(5):879-885. doi: 10.1007/s00296-018-3993-5. Epub 2018 Feb 15.
    https://www.ncbi.nlm.nih.gov/pubmed/29450637
  • Yildirim T, Yilmaz R, Uzerk Kibar M, Erdem Y.
    Canakinumab treatment in renal transplant recipients with familial Mediterranean fever.
    J Nephrol. 2018 Jun;31(3):453-455. doi: 10.1007/s40620-018-0475-5. Epub 2018 Feb 14.
    https://www.ncbi.nlm.nih.gov/pubmed/29446001
  • Poddighe D, Romano M, Gattinara M, Gerloni V.
    Biologics for the treatment of Juvenile Idiopathic Arthritis.
    Curr Med Chem. 2018 May 21. doi: 10.2174/0929867325666180522085716. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29788871
  • Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M, Manna R, Cimaz R, Priori R, Talarico R, de Marchi G, Frassi M, Gallizzi R, Soriano A, Alessio M, Cammelli D, Maggio MC, Gentileschi S, Marcolongo R, La Torre F, Fabiani C, Colafrancesco S, Ricci F, Galozzi P, Viapiana O, Verrecchia E, Pardeo M, Cerrito L, Cavallaro E, Olivieri AN, Paolazzi G, Vitiello G, Maier A, Silvestri E, Stagnaro C, Valesini G, Mosca M, de Vita S, Tincani A, Lapadula G, Frediani B, De Benedetti F, Iannone F, Punzi L, Salvarani C, Galeazzi M, Angotti R, Messina M, Tosi GM, Rigante D, Cantarini L; “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology).
    Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study.
    Clin Rheumatol. 2018 May 17. doi: 10.1007/s10067-018-4119-x. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29770930
 
ABRIL 2018
  • Opoka-Winiarska V, Żuber Z, Alexeeva E, Chasnyk V, Nikishina I, Dębowska G, Smolewska E.
    Long-term, interventional, open-label extension study evaluating the safety of tocilizumab treatment in patients with polyarticular-course juvenile idiopathic arthritis from Poland and Russia who completed the global, international CHERISH trial.
    J Rheumatol. 2018 Apr 15. pii: jrheum.171006. doi: 10.3899/jrheum.171006. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/29654485
  • Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, Akikusa JD, Al-Mayouf SM, Antón J, Avcin T, Berard RA, Beresford MW, Burgos-Vargas R, Cimaz R, De Benedetti F, Demirkaya E, Foell D, Itoh Y, Lahdenne P, Morgan EM, Quartier P, Ruperto N, Russo R, Saad-Magalhães C, Sawhney S, Scott C, Shenoi S, Swart JF, Uziel Y, Vastert SJ, Smolen JS.
    Treating juvenile idiopathic arthritis to target: recommendations of an international task force.
    Ann Rheum Dis. 2018 Apr 11. pii: annrheumdis-2018-213030. doi: 10.1136/annrheumdis-2018-213030. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29643108
  • Bielak M, Husmann E, Weyandt N, Haas JP, Hügle B, Horneff G, Neudorf U, Lutz T, Lilienthal E, Kallinich T, Tenbrock K, Berendes R, Niehues T, Wittkowski H, Weißbarth-Riedel E, Heubner G, Oommen P, Klotsche J, Foell D, Lainka E.
    IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).
    Pediatr Rheumatol Online J. 2018 Apr 5;16(1):22. doi: 10.1186/s12969-018-0236-y.
    https://www.ncbi.nlm.nih.gov/pubmed/29622022
  • Chen Y, Zou K, Sun J, Yang Y, Liu G.
    Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis.
    Pharmacogenomics. 2018 Apr;19(6):529-538. doi: 10.2217/pgs-2017-0208. Epub 2018 Mar 28.
    https://www.ncbi.nlm.nih.gov/pubmed/29589488
  • M F Silva J, Ladomenou F, Carpenter B, Chandra S, Sedlacek P, Formankova R, Grandage V, Friswell M, Cant AJ, Nademi Z, Slatter MA, Gennery AR, Hambleton S, Flood TJ, Lucchini G, Chiesa R, Rao K, Amrolia PJ, Brogan P, Wedderburn LR, Glanville JM, Hough R, Marsh R, Abinun M, Veys P.
    Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis.
    Blood Adv. 2018 Apr 10;2(7):777-786. doi: 10.1182/bloodadvances.2017014449.
    https://www.ncbi.nlm.nih.gov/pubmed/29618462
  • Ringold S, Nigrovic PA, Feldman BM, Tomlinson GA, von Scheven E, Wallace CA, Huber AM, Schanberg LE, Li SC, Weiss PF, Fuhlbrigge RC, Morgan EM, Kimura Y.
    The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans: Toward Comparative Effectiveness in the Pediatric Rheumatic Diseases.
    Arthritis Rheumatol. 2018 May;70(5):669-678. doi: 10.1002/art.40395. Epub 2018 Mar 31.
    https://www.ncbi.nlm.nih.gov/pubmed/29333701
 
MARZO 2018
  • Marino A, Real-Fernández F, Rovero P, Giani T, Pagnini I, Cimaz R, Simonini G.
    Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations.
    Clin Rheumatol. 2018 Mar 5. doi: 10.1007/s10067-018-4057-7. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29508177
  • Chen Y, Zou K, Sun J, Yang Y, Liu G.
    Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis.
    Pharmacogenomics. 2018 Mar 28. doi: 10.2217/pgs-2017-0208. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29589488
  • Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, Kawabe S.
    Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
    Mod Rheumatol. 2018 Mar 26:1-12.
    https://www.ncbi.nlm.nih.gov/pubmed/29578355
  • Rubbert-Roth A, Furst DE, Nebesky JM, Jin A, Berber E.
    A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.
    Rheumatol Ther. 2018 Mar 3. doi: 10.1007/s40744-018-0102-x. [Epub ahead of print] 
    https://www.ncbi.nlm.nih.gov/pubmed/29502236
  • Okihiro A, Hasija R, Fung L, Cameron B, Feldman BM, Laxer R, Schneider R, Silverman E, Spiegel L, Yeung RSM, Tse SML.
    Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study.
    Pediatr Rheumatol Online J. 2018 Mar 14;16(1):17.
    https://www.ncbi.nlm.nih.gov/pubmed/29540190
  • Bhat T, Coughlin CC.
    Mood changes with methotrexate therapy for dermatologic disease.
    Pediatr Dermatol. 2018 Mar;35(2):253-254.
    https://www.ncbi.nlm.nih.gov/pubmed/29315793
 
FEBRERO 2018
  • Schoemaker CG, van Dijkhuizen EHP, Vastert SJ.
    Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients
    Pediatr Rheumatol Online J. 2018 Feb 15;16(1):13. doi: 10.1186/s12969-018-0229-x.
    https://www-ncbi-nlm-nih-gov/pubmed/29448947
  • Höfel L, Eppler B, Storf M, Schnöbel-Müller E, Haas JP, Hügle B.
    Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing - treatment protocol and preliminary results
    Pediatr Rheumatol Online J. 2018 Feb 13;16(1):11. doi: 10.1186/s12969-018-0228-y.
    https://www-ncbi-nlm-nih-gov/pubmed/29433504
  • Beukelman T, Xie F, Chen L, Horton DB, Lewis JD, Mamtani R, Mannion MM, Saag KG, Curtis JR.
    Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors
    Ann Rheum Dis. 2018 Feb 9. pii: annrheumdis-2017-212613. doi: 10.1136/annrheumdis-2017-212613
    https://www-ncbi-nlm-nih-gov/pubmed/29440001
  • Klotsche J, Minden K, Niewerth M, Horneff G.
    Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
    Ann Rheum Dis. 2018 Feb 16. pii: annrheumdis-2017-211968. doi: 10.1136/annrheumdis-2017-211968. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29453217
  • Albert D.
    Prescribing for Children with Rheumatic Disease: Perceived Treatment Approaches between Pediatric and Adult Rheumatologists.
    Arthritis Care Res (Hoboken). 2018 Feb 26. doi: 10.1002/acr.23552. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29481725
  • Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ.
    Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
    Ann Rheum Dis. 2018 Feb 22. pii: annrheumdis-2017-212608. doi: 10.1136/annrheumdis-2017-212608. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29472362
 
ENERO 2018
  • Lee WJ, Lee TA, Suda KJ, Calip GS, Briars L, Schumock GT.
    Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.
    Rheumatology (Oxford). 2018 Feb 1;57(2):273-282. doi: 10.1093/rheumatology/kex049.
    https://www.ncbi.nlm.nih.gov/pubmed/28431162

 
DICIEMBRE 2017
 
NOVIEMBRE 2017
  • Moghadam-Kia S, Aggarwal R, Oddis CV.
    Biologics for idiopathic inflammatory myopathies.
    Curr Opin Rheumatol. 2017 Nov;29(6):645-651
    https://www.ncbi.nlm.nih.gov/pubmed/28817464
  • Horneff G, Peitz J, Kekow J, Foell D.
    Canakinumab for first line steroid-free treatment in a child with systemic-onset juvenile idiopathic arthritis.
    Scand J Rheumatol. 2017 Nov;46(6):500-501
    https://www.ncbi.nlm.nih.gov/pubmed/28266235
  • Correll CK, Bullock DR, Cafferty RM, Vehe RK.
    Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.
    Clin Rheumatol. 2017 Nov 4
    https://www.ncbi.nlm.nih.gov/pubmed/29103180
  • Langley RG, Kasichayanula S, Trivedi M, Aras GA, Kaliyaperumal A, Yuraszeck T, Gibbs J, Gibbs M, Kricorian G, Paller AS.
    Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
    J Clin Pharmacol. 2017 Nov 6
    https://www.ncbi.nlm.nih.gov/pubmed/29106714
  • Stoll ML, Grubbs JA, Beukelman T, Mannion ML, Jester TW, Cron RQ, Crain MJ.
    Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study.
    Pediatr Rheumatol Online J. 2017 Nov 9;15(1):79
    https://www.ncbi.nlm.nih.gov/pubmed/29121953
 
OCTUBRE 2017
  • Mittal L, Zhang L, Feng R, Werth VP.
    Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: a retrospective cohort study.
    J Am Acad Dermatol. 2017 Oct 5. pii: S0190-9622(17)32466-0. doi: 10.1016/j.jaad.2017.09.061. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/28989103
 
AGOSTO 2017
  • Murias S, Magallares L, Albizuri F, Pascual-Salcedo D, Dreesen E, Mulleman D.
    Current Practices for Therapeutic Drug Monitoring of Biopharmaceuticals in Pediatrics.
    Ther Drug Monit. 2017 Aug;39(4):370-378. doi: 10.1097/FTD.0000000000000423.
    https://www.ncbi.nlm.nih.gov/pubmed/28703718
 
JULIO 2017
  • Ahmet A, Brienza V, Tran A, Lemieux J, Aglipay M, Barrowman N, Duffy C, Roth J, Jurencak R.
    Frequency and Duration of Adrenal Suppression Following Glucocorticoid Therapy in Children With Rheumatic Diseases.
    Arthritis Care Res (Hoboken). 2017 Aug;69(8):1224-1230. doi: 10.1002/acr.23123. Epub 2017 Jul 10.
    https://www.ncbi.nlm.nih.gov/pubmed/27723273
 
JUNIO 2017
  • Zhang Y, Milojevic D.
    Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.
    Paediatr Drugs. 2017 Jun;19(3):193-211.
    https://www.ncbi.nlm.nih.gov/pubmed/28290112
  • López-Ferrer A, Laiz A, Puig L.
    The safety of ustekinumab for the treatment of psoriatic arthritis.
    Expert Opin Drug Saf. 2017 Jun;16(6):733-742.
    https://www.ncbi.nlm.nih.gov/pubmed/28441904
  • Falvey S, Shipman L, Ilowite N, Beukelman T.
    Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis.
    Pediatr Rheumatol Online J. 2017 Jun 19;15(1):52
    https://www.ncbi.nlm.nih.gov/pubmed/28629458
  • Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J, Gordon P, Christidis D, Galloway S, Hayes E, Jeffries A, Mercer S, Mooney J, van Leuven S, Galloway J; BSR and BHPR Standards, Guidelines and Audit Working Group.
    BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.
    Rheumatology (Oxford). 2017 Jun 1;56(6):865-868.
    https://www.ncbi.nlm.nih.gov/pubmed/28339817
  • Kossi S, Dadoun S, Geri G, Hermet A, Fautrel B, Dougados M, Gossec L.
    Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patients.
    Rheumatology (Oxford). 2017 Jun 1;56(6):896-900.
    https://www.ncbi.nlm.nih.gov/pubmed/28073957
  • Bragnes Y, Boshuizen R, de Vries A, Lexberg Å, Østensen M.
    Low level of Rituximab in human breast milk in a patient treated during lactation.
    Rheumatology (Oxford). 2017 Jun 1;56(6):1047-1048.
    https://www.ncbi.nlm.nih.gov/pubmed/28339781
  • Chausset A, Fargeix T, Pereira B, Echaubard S, Duquesne A, Desjonquères M, Freychet C, Belot A, Merlin E.
    MISS questionnaire in French version: a good tool for children and parents to assess methotrexate intolerance.
    Clin Rheumatol. 2017 Jun;36(6):1281-1288
    https://www.ncbi.nlm.nih.gov/pubmed/28477218
  • Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, Mcalindon T.
    2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
    Arthritis Care Res (Hoboken). 2017 Jun 6 doi: 10.1002/acr.23279. [ [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/28585410
 
MAYO 2017
  • Brunner HI, Ruperto N, Tzaribachev N, Horneff G, Chasnyk VG, Panaviene V, Abud-Mendoza C, Reiff A, Alexeeva E, Rubio-Pérez N, Keltsev V, Kingsbury DJ, Del Rocio Maldonado Velázquez M, Nikishina I, Silverman ED, Joos R, Smolewska E, Bandeira M, Minden K, van Royen-Kerkhof A, Emminger W, Foeldvari I, Lauwerys BR, Sztajnbok F, Gilmer KE, Xu Z, Leu JH, Kim L, Lamberth SL, Loza MJ, Lovell D, Martini A.
    Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
    Ann Rheum Dis. 2017 May 15. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28507219
  • Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, Mcalindon T.
    2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
    Arthritis Care Res (Hoboken). 2017 Jun 6. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28585410
  • Gentileschi S, Rigante D, Vitale A, Sota J, Frediani B, Galeazzi M, Cantarini L.
    Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.
    Clin Rheumatol. 2017 May 23. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/28536823
  • Komaki Y, Yamada A, Komaki F, Kudaravalli P, Micic D, Ido A, Sakuraba A.
    Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis.
    J Autoimmun. 2017 May;79:4-16. doi: 10.1016/j.jaut.2017.02.003.
    https://www.ncbi.nlm.nih.gov/pubmed/?term=28209290
  • Goodman DM.
    Pediatric clinical trials-number needed to recruit.
    J Pediatr. 2017 May;184:1-2. doi: 10.1016/j.jpeds.2017.03.011.
    https://www.ncbi.nlm.nih.gov/pubmed/?term=28434563
  • Stefanska AM, Distlerová D, Musaus J, Olski TM, Dunder K, Salmonson T, Mentzer D, Müller-Berghaus J, Hemmings R, Veselý R.
    Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.
    Arch Dis Child. 2017 May 29. [Epub ahead of print] Review.
    https://www.ncbi.nlm.nih.gov/pubmed/28554892
 
ABRIL 2017
  • Mauro A, Rigante D, Cimaz R.
    Investigational drugs for treatment of juvenile idiopathic arthritis
    Expert Opin Investig Drugs. 2017 Apr;26(4):381-387. doi: 10.1080/13543784.2017.1301929. Epub 2017 Mar 12. Review.
    https://www.ncbi.nlm.nih.gov/pubmed/28277884
 
MARZO 2017
  • Scott LJ.
    Sarilumab: First Global Approval.
    Drugs. 2017 Apr;77(6):705-712.
    https://www.ncbi.nlm.nih.gov/pubmed/28290137
  • Roszkiewicz J, Smolewska E.
    In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis-Are We Getting Closer to Personalised Medicine?
    Curr Rheumatol Rep. 2017 Apr;19(4):19. doi: 10.1007/s11926-017-0646-8
    https://www.ncbi.nlm.nih.gov/pubmed/28361333
  • Zhang X, Chen YC, Terao K.
    Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis.
    Expert Rev Clin Pharmacol. 2017 Mar 15:1-12. doi: 10.1080/17512433.2017.1300058. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/28293968
  • Lee M, Isaacs J.
    The novel use of combined IL-1 and IL-6 inhibition in a patient with severe, aggressive, erosive, systemic-onset juvenile idiopathic arthritis.
    Eur J Rheumatol. 2017 Mar;4(1):68-69. doi: 10.5152/eurjrheum.2016.055.
    https://www.ncbi.nlm.nih.gov/pubmed/28293458
FEBRERO 2017
  • Nakamura H, Sugai T, Kato M, Hatanaka KC, Atsumi T
    Subcutaneous panniculitis-like T-cell lymphoma with haemophagocytic syndrome during tocilizumab therapy for juvenile idiopathic arthritis.
    Clin Exp Rheumatol. 2017 Jan-Feb;35(1):174. Epub 2017 Jan 5.
    https://www.ncbi.nlm.nih.gov/pubmed/28079502
 
ENERO 2017
  • Scheuern A1, Tyrrell PN2, Haas JP1, Hügle B3.
    Countermeasures against methotrexate intolerance in juvenile idiopathic arthritis instituted by parents show no effect.
    Rheumatology (Oxford). 2017 Jan 24. pii: kew507. doi: 10.1093/rheumatology/kew507. [Epub ahead of print] https://www.ncbi.nlm.nih.gov/pubmed/28122960
  • Brachat AH, Grom AA, Wulffraat N, Brunner HI, Quartier P, Brik R, McCann L, Ozdogan H, Rutkowska-Sak L, Schneider R, Gerloni V, Harel L, Terreri M, Houghton K, Joos R, Kingsbury D, Lopez-Benitez JM, Bek S, Schumacher M, Valentin MA, Gram H, Abrams K, Martini A, Lovell DJ, Nirmala NR, Ruperto N; Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy.
    Arthritis Res Ther. 2017 Jan 23;19(1):13. doi: 10.1186/s13075-016-1212-x.
    https://www.ncbi.nlm.nih.gov/pubmed/28115015
DICIEMBRE 2016
  • Lakhanpal A, Brahn E.
    Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.
    Clin Rheumatol. 2016 Dec;35(12):2869-2875.
    https://www.ncbi.nlm.nih.gov/pubmed/27714482
  • Windschall D, Horneff G.
    Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
    Clin Rheumatol. 2016 Dec;35(12):2925-2931.
    https://www.ncbi.nlm.nih.gov/pubmed/27709443 
  • Verazza S, Davì S, Consolaro A, Bovis F, Insalaco A, Magni-Manzoni S, Nicolai R, Marafon DP, De Benedetti F, Gerloni V, Pontikaki I, Rovelli F, Cimaz R, Marino A, Zulian F, Martini G, Pastore S, Sandrin C, Corona F, Torcoletti M, Conti G, Fede C, Barone P, Cattalini M, Cortis E, Breda L, Olivieri AN, Civino A, Podda R, Rigante D, La Torre F, D'Angelo G, Jorini M, Gallizzi R, Maggio MC, Consolini R, De Fanti A, Muratore V, Alpigiani MG, Ruperto N, Martini A, Ravelli A; Italian Pediatric Rheumatology Study Group.
    Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
    Pediatr Rheumatol Online J. 2016 Dec 20;14(1):68.
    https://www.ncbi.nlm.nih.gov/pubmed/27993144
 
NOVIEMBRE 2016
  • Harrington J, Holmyard D, Silverman E, Sochett E, Grynpas M.
    Bone histomorphometric changes in children with rheumatic disorders on chronic glucocorticoids.
    Pediatr Rheumatol Online J. 2016 Nov 10;14(1):58.
    https://www.ncbi.nlm.nih.gov/pubmed/27832795
 
OCTUBRE 2016
  • McDonagh JE, Shaw KL, Prescott J, Smith FJ, Roberts R, Gray NJ.
    "Sometimes I feel like a pharmacist": identity and medication use among adolescents with juvenile arthritis.
    Pediatr Rheumatol Online J. 2016 Oct 19;14(1):57.
    https://www.ncbi.nlm.nih.gov/pubmed/27756328
 
AGOSTO 2016
 
JULIO 2016
  • Davies HD; COMMITTEE ON INFECTIOUS DISEASES.
    Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children.
    Pediatrics. 2016 Aug;138(2). pii: e20161209. doi: 10.1542/peds.2016-1209. Epub 2016 Jul 18.
    http://www.ncbi.nlm.nih.gov/pubmed/27432853
  • Orrock JE, Ilowite NT.
    Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
    Expert Rev Clin Pharmacol. 2016 Aug;9(8):1015-24. doi: 10.1080/17512433.2016.1204910. Epub 2016 Jul 6.
    http://www.ncbi.nlm.nih.gov/pubmed/27367267
 
JUNIO 2016
  • Fráňová J, Fingerhutová Š, Kobrová K, Srp R, Němcová D, Hoza J, Uher M, Saifridová M, Linková L, Doležalová P.
    Methotrexate efficacy, but not its intolerance, is associated with the dose and route of administration.
    Pediatr Rheumatol Online J. 2016 Jun 14;14(1):36. doi: 10.1186/s12969-016-0099-z
    http://www.ncbi.nlm.nih.gov/pubmed/27301536
  • Sterba Y, Ilowite N.
    Biologics in Pediatric Rheumatology: Quo Vadis?
    Curr Rheumatol Rep. 2016 Jul;18(7):45. doi: 10.1007/s11926-016-0593-9
    http://www.ncbi.nlm.nih.gov/pubmed/27306623
 
MAYO 2016
 
ABRIL 2016
 
MARZO 2016
 
FEBRERO 2016
  • Nguyen TA, Celano NJ, Matiz C.
    Palisaded Neutrophilic Granulomatous Dermatitis in a Child with Juvenile Idiopathic Arthritis on Etanercept.
    Pediatr Dermatol. 2016 Mar;33(2):e156-7. doi: 10.1111/pde.12797. Epub 2016 Feb 10.
    http://www.ncbi.nlm.nih.gov/pubmed/26860064
  • Taddio A, Cattalini M, Simonini G, Cimaz R.
    Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.
    Expert Rev Clin Immunol. 2016 Feb 19:1-9. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26809126
  • Lopalco G, Rigante D, Giannini M, Galeazzi M, Lapadula G, Iannone F, Cantarini L.
    Safety profile of anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders.
    Clin Exp Rheumatol. 2016 Feb 26. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26940286
 
DICIEMBRE 2015
 
  • Calzada-Hernández J, Anton-López J, Bou-Torrent R, Iglesias-Jiménez E, Ricart-Campos S, Martín de Carpi J; Carmen García de Vicuña Muñoz de la Nava, Torrente-Segarra V, Sánchez-Manubens J, Giménez-Roca C, Rozas-Quesada L, Juncosa-Morros MT, Fortuny C, Noguera-Julian A.
    Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study.

    Pediatr Rheumatol Online J. 2015 Dec 3;13(1):54. doi: 10.1186/s12969-015-0054-4.
    http://www.ncbi.nlm.nih.gov/pubmed/26635208
  • Vaz JL, Fernandes V, Nogueira F, Arnóbio A, Levy RA.
    Infliximab-induced autoantibodies: a multicenter study.
    Clin Rheumatol. 2015 Dec 17.
    http://www.ncbi.nlm.nih.gov/pubmed/26676808
  • Hügle B, Horneff G.
    The Role of Synthetic Drugs in the Biologic Era: Therapeutic Strategies for Treating Juvenile Idiopathic Arthritis.

    Expert Opin Pharmacother. 2015 Dec 17.
    http://www.ncbi.nlm.nih.gov/pubmed/26678914
 
NOVIEMBRE 2015
 
  • Agapitos Patakas, Rui-Ru Ji, William Weir, Sean E. Connolly, Robert A. Benson, Steven G. Nadler, James M Brewer, Iain B McInnes and Paul Garside
    Abatacept inhibits T cell priming by inducing of a unique transcriptional profile that reduces their ability to activate antigen presenting cells
    Arthritis & Rheumatology
    DOI: 10.1002/art.39470
    Abstract
  • Doyt L. Conn
    Is the Availability of Delayed Release Prednisone an Important Clinical Advance?
    Arthritis Care & Research
    DOI: 10.1002/acr.22745
    Abstract
  • Matthew Laurence Stoll, Yoginder Nath Vaid, Saurabh Guleria, Timothy Beukelman, Peter Daniel Waite, and Randy Quentin Cron
    Magnetic Resonance Imaging Findings following Intraarticular Infliximab Therapy for Refractory Temporomandibular Joint Arthritis among Children with Juvenile Idiopathic Arthritis

    J Rheumatol November 2015 42(11):2155-2159; doi:10.3899/jrheum.150308
    Abstract
  • Anna Felis-Giemza and Robert J. Moots
    Measurement of anti-drug antibodies to biologic drugs

    Rheumatology (2015) 54 (11): 1941-1943 doi:10.1093/rheumatology/kev279
    Extract
  • Tania S. Amin, Sian Shenton, Kathleen Mulligan, Lucy R. Wedderburn, Mark Wood, Vanessa VanRooyen, and Valentina Leone
    Strategies for the prevention and management of methotrexate-related nausea and vomiting in juvenile idiopathic arthritis: results of a UK Paediatric Rheumatology prescriber survey
    Rheumatology (2015) 54 (11): 2108-2109 doi:10.1093/rheumatology/kev259
    Extract
 
OCTUBRE 2015
  • Hawwa AF, AlBawab A, Rooney M, Wedderburn LR, Beresford MW, McElnay JC.
    Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study
    Arthritis Res Ther. 2015 Oct 22;17(1):295.
    http://www.ncbi.nlm.nih.gov/pubmed/26493320
  • Horneff G.
    Biologic-Associated Infections in Pediatric Rheumatology
    Curr Rheumatol Rep. 2015 Nov;17(11):66. doi: 10.1007/s11926-015-0542-z.
    http://www.ncbi.nlm.nih.gov/pubmed/26385753 
  • Ding HJ, Denniston AK, Rao VK, Gordon C.
    Hydroxychloroquine-related retinal toxicity
    Rheumatology (Oxford). 2015 Oct 1. pii: kev357. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/26428520
 
AGOSTO 2015
  • Rondeau JM, Ramage P, Zurini M, Gram H.
    The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.
    MAbs. 2015 Aug 18:0. EPUB ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/26284424
 
JULIO 2015
  • Horneff G
    Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.
    Expert Opin Drug Saf. 2015 Jul;14(7):1111-26. doi: 10.1517/14740338.2015.1042453.
    http://www.ncbi.nlm.nih.gov/pubmed/26084637
 
JUNIO 2015
  • Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH.
    Rituximab for IgG4-related disease: a prospective, open-label trial.
    Ann Rheum Dis. 2015 Jun;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605.
    http://www.ncbi.nlm.nih.gov/pubmed/25667206
  •  Mercer LK, Lunt M, Low AL, Dixon WG, Watson KD, Symmons DP, Hyrich KL; BSRBR Control Centre Consortium.
    Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Ann Rheum Dis. 2015 Jun;74(6):1087-93. doi: 10.1136/annrheumdis-2013-204851.
    http://www.ncbi.nlm.nih.gov/pubmed/24685910
  •  Scheinberg M.
    Therapy: Facing up to biosimilar agents-the ACR position.
    Nat Rev Rheumatol. 2015 Jun;11(6):322-4. doi: 10.1038/nrrheum.2015.57.
    http://www.ncbi.nlm.nih.gov/pubmed/25907701
 
MAYO 2015
    • Hermine I Brunner, Nicolino Ruperto, Zbigniew Zuber, Caroline Keane, Olivier Harari, Andrew Kenwright, et al for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
      Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
      Ann Rheum Dis. 2015;74:1110-1117 doi:10.1136/annrheumdis-2014-205351
      http://ard.bmj.com/content/74/6/1110.abstract
 
ABRIL 2015
  • Bulatović Ćalasan M, Vastert SJ, Scholman RC, Verweij F, Klein M, Wulffraat NM, Prakken BJ, van Wijk F.
    Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis
    Rheumatology (Oxford). 2015 Apr 14. pii: kev101. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25877908
 
MARZO 2015
    • Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, Touitou I, Koné-Paut I; MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on the behalf of CRI (Club Rhumatisme et Inflammation).
      Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
      Orphanet J Rare Dis. 2015 Feb 15;10(1):19. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25758134
    • Ungprasert P, Srivali N, Wijarnpreecha K, Charoenpong P, Knight EL.
      Non-steroidal anti-inflammatory drugs and risk of venous thromboembolism: a systematic review and meta-analysis
      Rheumatology (2015) 54 (4): 736-742. doi:10.1093/rheumatology/keu408
      http://rheumatology.oxfordjournals.org/content/54/4/736.abstract
    • Strand V, Burmester GR, Zerbini CAF, Mebus CA, Zwillich SH, Gruben D, Wallenstein GV.
      Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial
      Arthritis Care Res (Hoboken) 2015; 67(4):475-483. DOI: 10.1002/acr.22453
      http://onlinelibrary.wiley.com/doi/10.1002/acr.22453/epdf
    • Séïté JF, Hillion S, Harbonnier T, Pers JO.
      Review: intravenous immunoglobulin and B cells: when the product regulates the producer.
      Arthritis Rheumatol. 2015 Mar;67(3):595-603. doi: 10.1002/art.38910
      http://www.ncbi.nlm.nih.gov/pubmed/25303681
DICIEMBRE 2014
  • Burnett HF, Ungar WJ, Regier DA, Feldman BM, Miller FA.
    Parents' willingness to pay for biologic treatments in juvenile idiopathic arthritis.
    Value Health. 2014 Dec;17(8):830-7. doi: 10.1016/j.jval.2014.08.2668. Epub 2014 Nov 6.
    http://www.ncbi.nlm.nih.gov/pubmed/25498778
    Präger TM, Meyer P, Rafayelyan S, Minden K, Jost-Brinkmann PG.
    Effect of methotrexate on the mandibular development of arthritic rabbits.
    Eur J Orthod. 2014 Dec 17. pii: cju070. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/25518996
  • Shimizu M, Hamaguchi Y, Ishikawa S, Ueno K, Yachie A.
    Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.
    Mod Rheumatol. 2014 Dec 15:1-2.
    http://www.ncbi.nlm.nih.gov/pubmed/25496406
  • Berard RA, Laxer RM.
    Early aggressive therapy for patients with juvenile idiopathic arthritis: are we there yet?
    J Rheumatol. 2014 Dec;41(12):2343-6.
    http://www.ncbi.nlm.nih.gov/pubmed/25452178
 
NOVIEMBRE 2014
 
OCTUBRE 2014
  • Ringold S, Hendrickson A, Abramson L, Beukelman T, Blier PR, Bohnsack J, Chalom EC, Gewanter HL, Gottlieb B, Hollister R, Hsu J, Hudgins A, Ilowite NT, Klein-Gitelman M, Lindsley C, LopezBenitez JM, Lovell DJ, Mason T, Milojevic D, Moorthy LN, Nanda K, Onel K, Prahalad S, Rabinovich CE, Ray L, Rouster-Stevens K, Ruth N, Shishov M, Spalding S, Syed R, Stoll M, Vehe RK, Weiss JE, White AJ, Wallace CA, Sobel RE.
    A novel method to collect medication adverse events in juvenile arthritis: Results from the Childhood Arthritis and rheumatology research alliance enhanced drug safety surveillance project (EDSSP).
    Arthritis Care Res (Hoboken). 2014 Oct 20. doi: 10.1002/acr.22487. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25331530 
  • Windschall D, Müller T, Becker I, Horneff G.
    Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years.
    Rheumatol Int. 2014 Sep 11. [Epub ahead of print]
    http://www.ncbi.nlm.nih.gov/pubmed/25208527 
  • Schmeling H, Horneff G, Benseler SM, Fritzler MJ.
    Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?
    Nat Rev Rheumatol. 2014 Nov;10(11):682-690. doi: 10.1038/nrrheum.2014.140. Epub 2014 Aug 12. Review.
    http://www.ncbi.nlm.nih.gov/pubmed/25112604 
  • Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
    Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Arthritis Rheumatol. 2014 Sep;66(9):2580-9. doi: 10.1002/art.38741.
    http://www.ncbi.nlm.nih.gov/pubmed/24942886 
  • K A van Schie, M H Hart, E R de Groot, S Kruithof, L A Aarden, G J Wolbink, T Rispens
    Concise report: The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region
    Ann Rheum Dis Published Online First: 23 October 2014
    doi:10.1136/annrheumdis-2014-206237
    http://ard.bmj.com/content/early/2014/10/23/annrheumdis-2014-206237.abstract
 
SEPTIEMBRE 2014
 
AGOSTO 2014
  • Mannion ML, Xie F, Curtis JR, Beukelman T.
    Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors.
    J Rheumatol. 2014 Aug 1.
    http://www.ncbi.nlm.nih.gov/pubmed/25086081
 
JULIO 2014
  • Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, Muscal E, Deiva K, Andersen E, Eyre MR, Eleftheriou D, Brogan PA, Kneen R, Alper G, Anlar B, Wassmer E, Heineman K, Hemingway C, Riney CJ, Kornberg A, Tardieu M, Stocco A, Banwell B, Gorman MP, Benseler SM, Lim M.
    Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
    Neurology. 2014 Jul 8;83(2):142-50
    http://www.ncbi.nlm.nih.gov/pubmed/24920861
  • Scott LJ.
    Etanercept: A Review of Its Use in Autoimmune Inflammatory Diseases.
    Drugs. 2014 Jul 18. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/25034360
  • Dale RC1, Brilot F2, Duffy LV2, Twilt M2, Waldman AT2, Narula S2, Muscal E2, Deiva K2, Andersen E2, Eyre MR2, Eleftheriou D2, Brogan PA2, Kneen R2, Alper G2, Anlar B2, Wassmer E2, Heineman K2, Hemingway C2, Riney CJ2, Kornberg A2, Tardieu M2, Stocco A2, Banwell B2, Gorman MP2, Benseler SM2, Lim M2.
    Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
    Neurology. 2014 Jul 8;83(2):142-50. 
    http://www.ncbi.nlm.nih.gov/pubmed/24920861
  • [No authors listed]Discrepancy Between Clinical and Radiological Responses to Tocilizumab Treatment in Patients with Systemic-onset Juvenile Idiopathic Arthritis.
    J Rheumatol. 2014 Jul;41(7):1567.
    http://www.ncbi.nlm.nih.gov/pubmed/24986971
  • Windschall D1, Müller T, Becker I, Horneff G.
    Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-relatedarthritis and psoriasis arthritis.
    Clin Rheumatol. 2014 Jul 18.
    http://www.ncbi.nlm.nih.gov/pubmed/25034081
  • Sobel RE1, Lovell DJ2, Brunner HI2, Weiss JE3, Morris PW4, Gottlieb BS5, Chalom EC6, Jung LK7, Onel KB8, Petiniot L9, Goldsmith DP10, Nanda K11, Shishov M12, Abramsky S1, Young JP13, Giannini EH2.
    Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry.
    Pediatr Rheumatol Online J. 2014 Jul 16;12:29.
    http://www.ncbi.nlm.nih.gov/pubmed/25034081
  • Shimizu M1, Ueno K2, Ishikawa S2, Tokuhisa Y2, Inoue N2, Yachie A2.
    Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus.
    Rheumatology (Oxford). 2014 Jul 26.
    http://www.ncbi.nlm.nih.gov/pubmed/25065006
  • Autmizguine J1, Cohen-Wolkowiez M, Ilowite N; for the RAPPORT investigators.
    Rilonacept Pharmacokinetics in Children With Systemic Juvenile Idiopathic Arthritis.
    J Clin Pharmacol. 2014 Jul 30.
    http://www.ncbi.nlm.nih.gov/pubmed/25079592
MAYO 2014
  • Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK.
    Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years.
    J Rheumatol. 2014 May 15. pii: jrheum.131231. [Epub ahead of print]
  • Aeschlimann FA, Hofer KD, Cannizzaro Schneider E, Schroeder S, Lauener R, Saurenmann RK.
    Infliximab in Pediatric Rheumatology Patients: A Retrospective Analysis of Infusion Reactions and Severe Adverse Events During 2246 Infusions over 12 Years.
    J Rheumatol. 2014 May 15. pii: jrheum.131231. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24833759
 
MARZO 2014
  • Santer M, Ring N, Yardley L, Geraghty AW, Wyke S.
    Treatment non-adherence in pediatric long-term medical conditions: systematic review and synthesis of qualitative studies of caregivers' views.
    BMC Pediatr. 2014 Mar 4;14(1):63. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24593304
  • Tanaka T, Narazaki M, Ogata A, Kishimoto T.
    A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Semin Immunol. 2014 Mar 1. pii: S1044-5323(14)00010-4. doi: 10.1016/j.smim.2014.01.009. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24594001
 
FEBRERO 2014
  • Kingsbury DJ, Bader-Meunier B, Patel G, Arora V, Kalabic J, Kupper H.
    Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.
    Clin Rheumatol. 2014 Feb 2. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24487484
  • Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H.
    The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.
    Rheumatology (Oxford). 2014 Feb;53(2):213-22. doi: 10.1093/rheumatology/ket260. Epub 2013 Aug 14.
    http://www.ncbi.nlm.nih.gov/pubmed/23946436
  • Iannone F, La Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G.
    Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.
    J Rheumatol. 2014 Feb;41(2):286-92. doi: 10.3899/jrheum.130658. Epub 2014 Jan 15.
    http://www.ncbi.nlm.nih.gov/pubmed/24429167
  • Hashkes PJ, Becker ML, Cabral DA, Laxer RM, Paller AS, Rabinovich CE, Turner D, Zulian F.
    Methotrexate: new uses for an old drug.
    J Pediatr. 2014 Feb;164(2):231-6. doi: 10.1016/j.jpeds.2013.10.029.
    http://www.ncbi.nlm.nih.gov/pubmed/24286573
 
NOVIEMBRE 2013
 
OCTUBRE 2013
  • Frampton JE.
    Tocilizumab: A Review of Its Use in the Treatment of Juvenile Idiopathic Arthritis.
    Paediatr Drugs. 2013 Oct 24. [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/24155139
  • Lionetti G, Kimura Y, Schanberg LE, Beukelman T, Wallace CA, Ilowite NT, Winsor J, Fox K, Natter M, Sundy JS, Brodsky E, Curtis JR, Del Gaizo V, Iyasu S,Jahreis A, Meeker-O'Connell A, Mittleman BB, Murphy BM, Peterson ED, Raymond SC, Setoguchi S, Siegel JN, Sobel RE, Solomon D, Southwood TR, Vesely R, White PH, Wulffraat NM, Sandborg CI.
    Using Registries to Identify Adverse Events in Rheumatic Diseases.
    Pediatrics.2013 Oct 21. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/24144710
  • Prince FH, Solomon DH.
    Dosing of biologics in juvenile idiopathic arthritis: is the sky the limit?
    J Rheumatol. 2013 Oct;40(10):1643-5. doi: 10.3899/jrheum.130875.
    http://www.ncbi.nlm.nih.gov/pubmed/2408575
 
SEPTIEMBRE 2013
  • Ioannidis JP, Karassa FB, Druyts E, Thorlund K, Mills EJ
    Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales.
    Nat Rev Rheumatol 2013 Sep 3. doi: 10.1038/nrrheum.2013.134. [Epub ahead of print]http://www.ncbi.nlm.nih.gov/pubmed/23999553
 
MAYO 2013
PATROCINADORES

Área de Socios